Bayer Healthcare Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BAYER HEALTHCARE, and what generic alternatives to BAYER HEALTHCARE drugs are available?
BAYER HEALTHCARE has twenty-nine approved drugs.
There are twenty-eight US patents protecting BAYER HEALTHCARE drugs. There is one tentative approval on BAYER HEALTHCARE drugs.
There are four hundred and twenty-five patent family members on BAYER HEALTHCARE drugs in fifty-nine countries and forty-nine supplementary protection certificates in seventeen countries.
Summary for Bayer Healthcare
| International Patents: | 425 |
| US Patents: | 28 |
| Tradenames: | 24 |
| Ingredients: | 14 |
| NDAs: | 29 |
| Patent Litigation for Bayer Healthcare: | See patent lawsuits for Bayer Healthcare |
Drugs and US Patents for Bayer Healthcare
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Healthcare Llc | MYCELEX | clotrimazole | CREAM;TOPICAL | 018183-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Bayer Healthcare | VITRAKVI | larotrectinib sulfate | SOLUTION;ORAL | 211710-001 | Nov 26, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Bayer Healthcare | VITRAKVI | larotrectinib sulfate | SOLUTION;ORAL | 211710-001 | Nov 26, 2018 | RX | Yes | Yes | 10,668,072 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Bayer Healthcare | VITRAKVI | larotrectinib sulfate | SOLUTION;ORAL | 211710-001 | Nov 26, 2018 | RX | Yes | Yes | 11,191,766 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Bayer Healthcare Llc | CLARITIN | loratadine | TABLET, CHEWABLE;ORAL | 021891-002 | Nov 21, 2018 | OTC | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Bayer Healthcare | NUBEQA | darolutamide | TABLET;ORAL | 212099-001 | Jul 30, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Bayer Healthcare | ALIQOPA | copanlisib dihydrochloride | POWDER;INTRAVENOUS | 209936-001 | Sep 14, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Bayer Healthcare
International Patents for Bayer Healthcare Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 101410016 | ⤷ Try a Trial |
| Japan | 2013508447 | ⤷ Try a Trial |
| Spain | 2900243 | ⤷ Try a Trial |
| Eurasian Patent Organization | 201992103 | ⤷ Try a Trial |
| South Africa | 201202655 | ⤷ Try a Trial |
| Russian Federation | 2018137206 | ⤷ Try a Trial |
| Hong Kong | 1130629 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Bayer Healthcare Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3106463 | 11/2020 | Austria | ⤷ Try a Trial | PRODUCT NAME: LAROTRECTINIB UND/ODER PHARMAZEUTISCH AKZEPTABLE SALZE DAVON, INSBESONDERE LAROTRECTINIBSULFAT, EINSCHLIESSLICH LAROTRECTINIBHYDROGENSULFAT; REGISTRATION NO/DATE: EU/1/19/1385 20190923 |
| 3106463 | 2090009-8 | Sweden | ⤷ Try a Trial | PRODUCT NAME: LAROTRECTINIB,OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY LAROTRECTINIB SULFATE INCLUDING LAROTRECTINIB HYDROGEN SULFATE; REG. NO/DATE: EU/1/19/1385 20190923 |
| 1986495 | 122019000057 | Germany | ⤷ Try a Trial | PRODUCT NAME: SEDAXANE ODER EIN TAUTOMER HIERVON MIT METALAXYL-M UND MIT FLUDIOXONIL; NAT. REGISTRATION NO/DATE: 008594-00 20181218; FIRST REGISTRATION: NIEDERLANDE 15544 N 20171229 |
| 2493858 | CA 2020 00020 | Denmark | ⤷ Try a Trial | PRODUCT NAME: DAROLUTAMID EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT ELLER EN FARMACEUTISK ACCEPTABELT ESTER DERAF; REG. NO/DATE: EU/1/20/1432/001 20200330 |
| 1986495 | 33/2019 | Austria | ⤷ Try a Trial | PRODUCT NAME: SEDAXAN ODER EIN TAUTOMER DAVON, FLUDIOXONIL UND METALAXYL M; NAT. REGISTRATION NO/DATE: 3979-0 20181130; FIRST REGISTRATION: NL 29317 20171229 |
| 3106463 | 301033 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: LAROTRECTINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LAROTRECTINIBSULFAAT, MET INBEGRIP VAN LAROTRECTINIBSULFAAT MONOHYDRAAT; REGISTRATION NO/DATE: EU/1/19/1385 20190923 |
| 1986495 | CR 2020 00009 | Denmark | ⤷ Try a Trial | PRODUCT NAME: SEDAXAN ELLER EN TAUTOMER DERAF, FLUDIOXONIL OG METALAXYL M; NAT. REG. NO/DATE: 1-235 20191015; FIRST REG. NO/DATE: NL 15544 N 20171229 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
